

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)



(10) International Publication Number
WO 2022/159653 A3

(51) International Patent Classification:

C07K 16/2803 (2006.01) A61K 35/17 (2015.01)
C07K 14/725 (2006.01) C07K 14/705 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2022/013231

(22) International Filing Date:

21 January 2022 (21.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/140,752 22 January 2021 (22.01.2021) US

(71) Applicant: **ELPIS BIOPHARMACEUTICALS**

[US/US]; 128 Spring Street, Lexington, Massachusetts
02421 (US).

(72) Inventors: **CHEN, Yan**; c/o Elpis Biopharmaceuticals,

128 Spring Street, Lexington, Massachusetts 02421 (US).

NGUYEN, Jenna; c/o Elpis Biopharmaceuticals, 128

Spring Street, Lexington, Massachusetts 02421 (US).

ZHAO, Kehao; c/o Elpis Biopharmaceuticals, 128 Spring

Street, Lexington, Massachusetts 02421 (US). **ZHANG, Keming**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US).

(74) Agent: **CHEN, Yahua**; c/o McDermott Will & Emery LLP,

500 North Capitol Street, NW, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BISPECIFIC CHIMERIC ANTIGEN RECEPTORS BINDING TO CD19 AND CD22

FIG. 1

CD19 and CD22 receptor counts by qFlow



(57) Abstract: Bi-specific chimeric antigen receptors (CARs) capable of binding to both CD19 and CD22 and immune cells expressing such. Also provided herein are therapeutic uses of such immune cells (e.g., CAR-T cells) for eliminating disease cells such as cancer cells.

[Continued on next page]



WO 2022/159653 A3

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

13 April 2023 (13.04.2023)

(15) Information about Correction:

see Notice of 16 February 2023 (16.02.2023)